Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3564)	1/8/1998 9:58:00 AM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

fyi, note the projection of a $5B anti-HIV market in 2005. LONDON, Jan 8 (Reuters) - The European pharmaceutical industry will see sweeping consolidation in the early years of the 21st century, management consultancy Datamonitor said on Thursday. Acquisitions and mergers will be common for at least the next decade as major companies seek greater market share, Datamonitor said in a report, "Into the 21st Century: 2020 Visions." The industry will also be galvanised by companies' need to drive costs down and develop more efficient research and development spending, the report found. By 2005, national players will become insignificant in Western Europe's pharmaceutical industry and by 2010 the same will apply to Eastern Europe, Datamonitor said. The report said European drug companies Astra <ASTRa.ST> and Zeneca Group Plc <ZEN.L> would be particularly attractive acquisition targets because they have demonstrated good sales growth and particular product strengths. In a separate report, Datamonitor forecast that the global anti-HIV drug market would exceed $5 billion by 2005. Increased confidence in combination therapy has been primarily responsible for the dramatic surge in the use of HIV medications, Datamonitor said. It is likely that anti-HIV therapies will increasingly be used to treat earlier stages of the disease, thus reducing death rates and driving growth in the anti-HIV market, Datamonitor predicted. 07:51 01-08-98